# US 2024/0254438 A1 · Multi-regional human neural circuits in assembloids derived from pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254438 A1
- Document ID: US20240254438A1
- Status: Published application
- Kind: A1
- Application number: 18/561,236
- Filed: 2022-06-21
- Published: 2024-08-01
- Earliest claimed: 2021-06-21
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Sergiu P. Pasca; Ji-il Kim; Yuki Miura
- Web page: https://patentgrep.com/patent/US20240254438A1

## CPC

- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0619: {Neurons}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- C07K 14/50: Fibroblast growth factor [FGF]
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C12N 2500/36: Lipids
- C12N 2500/38: Vitamins
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2503/02: Drug screening
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- C12N 2533/52: Fibronectin; Laminin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Functional human hCS-hStrS-hDiS and hCS-hDiS-hStrS-hMbS assembloids are generated by in vitro culture. Complete systems are assembled from component cultured cell systems, where each cultured cell system is designed to provide specific sets of neural cells, and which components are functionally integrated in the assembled spheroid.

## Claims

### Claim 1

A method for producing functionally integrated human cortico-striatal-midbrain-thalamic-cortical assembled spheroids in vitro, the method comprising:
inducing in a pluripotent stem cell suspension culture a neural fate to provide a spheroid of neural progenitor cells wherein the pluripotent stem cell suspension culture is optionally an induced pluripotent stem cell suspension culture;
(i) differentiating the neural progenitor cells in a spheroid to differentiate into one or more of: human cortical spheroids (hCS), human striatum spheroids (hStrS), human midbrain spheroids (hMbS) and human diencephalic spheroids (hDiS); and
culturing the hCS, hStrS, and hDiS or hCS, hDiS, hStrS, and hMbS under conditions permissive for spheroid fusion into loop assembloids while maintaining for an extended period of time in neural medium; wherein an integrated structure is differentiated comprising interacting neurons that form a loop circuit.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurons comprise at least one allele associated with a neurologic disorder.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the pluripotent stem cell suspension culture is induced to a neural fate by culturing intact colonies of the pluripotent stem cells in medium comprising a dose of dorsomorphin (DM) or LDN 193189, and SB-431542 effective to induce pluripotent stem cells to a neural fate.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the suspension culture is feeder layer free.

### Claim 7 (depends on 1)

The method of claim 1, wherein cells are differentiated into neural progenitors by culture in neural medium comprising a dose of retinoic acid, FGF2 and EGF.

### Claim 8 (depends on 7)

The method of claim 7, further comprising differentiating neural progenitors by supplementing medium with an effective dose of an SHH pathway agonist, optionally supplemented with a gamma secretase inhibitor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the spheroids are then cultured in medium comprising an effective dose of BDNF; IGF; L-ascorbic acid; and cAMP to mature spinal cord spheroids.

### Claim 10 (depends on 1)

The method of claim 1, further comprising maintaining functionally integrated human hCS-hStrS-hDiS or hCS-hDiS-hStrS-hMbS assembloids thus produced for an extended period of time in neural medium lacking growth factors.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hDiS cells express TCF7L2.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method determining the effect of a candidate agent on human cortico-striatal-midbrain-thalamic-cortical circuits, the method comprising:
contacting the candidate agent with one or a panel of functionally integrated human hCS-hStrS-hDiS or hCS-hDiS-hStrS-hMbS assembled spheroids differentiated from induced human pluripotent stem cells (hiPSC) according to the method of claim 1, or a population of cells isolated therefrom; and determining the effect of the agent on morphologic, genetic or functional parameters.

### Claim 14 (depends on 13)

The method of claim 13, wherein a panel of functionally integrated human cortico-striatal-midbrain-thalamic-cortical assembled spheroids comprises at least 2 differing genotypes.

### Claim 15 (depends on 1)

An in vitro generated functionally integrated human c hCS-hStrS-hDiS or hCS-hDiS-hStrS-hMbS assembled spheroid produced by the method of claim 1.

### Claim 16

A method for producing a human diencephalic spheroid or organoid (hDIS), the method comprising:
(a) inducing a human pluripotent stem cell in suspension culture to a neural fate to provide a neural spheroid wherein the human pluripotent stem cell is optionally an induced human pluripotent stem cell;
(b) differentiating the neural spheroid into a diencephalic spheroid; and
(c) maintaining the diencephalic spheroid in neural medium such that the diencephalic spheroid comprises human diencephalic neurons.

### Claim 17 (depends on 16)

The method of claim 16, wherein the human diencephalic neurons comprise glutamatergic neurons expressing TCF7L2 and SLC17A6.

### Claim 18

(canceled)

### Claim 19 (depends on 16)

The method of claim 16, wherein inducing the human pluripotent stem cell in suspension culture to the neural fate in step (a) comprises culturing in a medium comprising one or more SMAD inhibitors, and an inhibitor of GSK-3, BMP7 and a sonic hedgehog pathway agonist.

### Claim 20 (depends on 19)

The method of claim 19, wherein the SMAD inhibitors are dorsomorphin (DM) or LDN 193189, and SB-431542, the sonic hedgehog pathway agonist is smoothened agonist (SAG), and the inhibitor of GSK-3 is CHIR99021.

### Claim 21

(canceled)

### Claim 22 (depends on 16)

The method of claim 16 wherein step (a) comprises culturing in a medium comprising the one or more SMAD inhibitors is for a period of from 4 to 10 days, and adding the inhibitor of GSK-3 to the medium after about 3 days of culture in the medium comprising the one or more SMAD inhibitors and adding the sonic hedgehog pathway agonist to the medium after about 7 days of culture in the medium comprising the one or more SMAD inhibitors and adding the BMP7 to the medium after about 12 days of culture in the medium comprising the one or more SMAD inhibitors.

### Claim 23 (depends on 16)

The method of claim 16, wherein differentiating the neural spheroid into a diencephalic spheroid in step (b) comprises:
transferring the neural spheroid to a suspension culture in neural medium supplemented with one or more SMAD inhibitors, and an inhibitor of GSK-3, BMP7 and a sonic hedgehog pathway agonist; and
culturing the neural spheroid in suspension culture in neural medium supplemented with brain-derived neurotrophic factor (BDNF), NT3, L-Ascorbic Acid, 5′-cyclic monophosphate sodium salt (cAMP), cis-4, 7, 10, 13, 16, 19-Docosahexaenoic acid (DHA), and DAPT.

### Claim 24 (depends on 23)

The method of claim 23, wherein the sonic hedgehog pathway agonist is smoothened agonist (SAG), the inhibitor of SMAD is dorsomorphin (DM) or LDN 193189, and SB-431542, and the inhibitor of GSK-3 is CHIR99021.

### Claim 25 (depends on 16)

A diencephalic spheroid obtained by the method of claim 16.
